Please assess the completion status of the following clinical trial:

Trial Title: Remimazolam Bolus for General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for general anesthesia~Exclusion Criteria:~1. Patients scheduled for liver surgery~2. Uncontrolled hypertension~3. Uncontrolled diabetes mellitus~4. Liver disease~5. Kidney disease~6. Intolerance or hypersensitivity to benzodiazepine~7. Addiction~8. Glaucoma~9. Heart failure~10. Peripheral vascular disease~11. Obstuctive lung disease~12. Patients scheduled for regional anesthesia before general anesthesia~13. Pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (0.02 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
- 2 (0.07 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
- 3 (0.12 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
- 4 (0.17 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
- 5(0.22 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
- 6(0.27 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
- 7 (0.02 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
- 8 (0.07 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
- 9 (0.12 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
- 10 (0.17 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
- 11 (0.22 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
- 12 (0.27 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.

Based on this trial design, predict the completion outcome and termination type (if applicable).